These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 5324060)

  • 1. Tolbutamde in the treatment of Parkinson's disease--a double blind trial.
    Hansen JM; Kristensen M
    Dan Med Bull; 1965 Dec; 12(7):181-4. PubMed ID: 5324060
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bromocriptine in the treatment of Parkinson's disease].
    Sepcić J; Ledić P
    Neurologija; 1982; 30(1-4):75-81. PubMed ID: 6765062
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlled trial of amantadine hydrochloride in Parkinson's disease.
    Jorgensen PB; Bergin JD; Haas L; Cuningham JA; Morah DD; Pollock M; Robinson RG; Spears GF
    N Z Med J; 1971 May; 73(468):263-7. PubMed ID: 4932146
    [No Abstract]   [Full Text] [Related]  

  • 4. Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease.
    Silver DE; Sahs AL
    Trans Am Neurol Assoc; 1971; 96():307-8. PubMed ID: 4945919
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic effects of Nicholin (CDP-choline): Parkinson's syndrome.--a double-blind study].
    Tsubaki T; Kase M; Ando K; Manaka N; Sato Y
    Nihon Rinsho; 1974 Nov; 32(11):3435-50. PubMed ID: 4616105
    [No Abstract]   [Full Text] [Related]  

  • 6. A double-blind evaluation of lysivane in the treatment of Parkinson's disease.
    Strang RR
    Br J Clin Pract; 1966 May; 20(5):249-51. PubMed ID: 5326485
    [No Abstract]   [Full Text] [Related]  

  • 7. A double-blind evaluation of S.D. 25 in the treatment of Parkinson's disease.
    Strang RR
    Curr Med Drugs; 1966 Dec; 7(4):20-6. PubMed ID: 5976205
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical evaluation of biperiden in Parkinson's disease.
    Strang RR
    Dis Nerv Syst; 1967 Mar; 28(3):191-3. PubMed ID: 5335879
    [No Abstract]   [Full Text] [Related]  

  • 9. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1993 Apr; 33(4):350-6. PubMed ID: 8489205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age bias in clinical trials of Parkinson's disease treatment.
    Rajapakse A; Rajapakse S; Playfer J
    J Am Geriatr Soc; 2008 Dec; 56(12):2353-4. PubMed ID: 19093937
    [No Abstract]   [Full Text] [Related]  

  • 12. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
    Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
    Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085.
    Pakkenberg H; Jensen I
    Adv Neurol; 1983; 37():151-7. PubMed ID: 6344587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease.
    Klawans HL; Tanner CM; Glatt S; Goetz CG
    Adv Neurol; 1983; 37():75-83. PubMed ID: 6344592
    [No Abstract]   [Full Text] [Related]  

  • 19. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor.
    Foster NL; Newman RP; LeWitt PA; Gillespie MM; Larsen TA; Chase TN
    Ann Neurol; 1984 Oct; 16(4):505-8. PubMed ID: 6149724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Which drug to use for the initiation of treatment for early Parkinson's disease].
    Marttila R
    Duodecim; 2004; 120(5):587-90. PubMed ID: 15060995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.